Protocol for a randomised controlled feasibility trial of exercise rehabilitation for people with postural tachycardia syndrome: the PULSE study by McGregor, Gordon et al.
  
 
Protocol for a randomised controlled 
feasibility trial of exercise rehabilitation for 
people with postural tachycardia syndrome: 
the PULSE study 
 
McGregor, G., Hee, S. W., Eftekhari, H., Holliday, N., Pearce, G., 
Sandhu, H., Simmonds, J., Joshi, S., Kavi, L., Bruce, J., Panikker, S., 
Lim, B. & Hayat, S. 
 
Published PDF deposited in Coventry University’s Repository  
 
Original citation:  
McGregor, G, Hee, SW, Eftekhari, H, Holliday, N, Pearce, G, Sandhu, H, Simmonds, J, Joshi, S, 
Kavi, L, Bruce, J, Panikker, S, Lim, B & Hayat, S 2020, 'Protocol for a randomised controlled 
feasibility trial of exercise rehabilitation for people with postural tachycardia syndrome: the 
PULSE study', Pilot and Feasibility Studies, vol. 6, 157. 
https://dx.doi.org/10.1186/s40814-020-00702-1 
 
 
DOI    10.1186/s40814-020-00702-1 
ESSN  2055-5784 
 
 
Publisher: BMC 
 
 
Open Access This article is licensed under a Creative Commons Attribution 4.0 
International License, which permits use, sharing, adaptation, distribution and 
reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and 
indicate if changes were made. The images or other third party material in this article are 
included in the article's Creative Commons licence, unless indicated otherwise in a credit 
line to the material. If material is not included in the article's Creative Commons licence 
and your intended use is not permitted by statutory regulation or exceeds the permitted 
use, you will need to obtain permission directly from the copyright holder. To view a copy 
of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons 
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) 
applies to the data made available in this article, unless otherwise stated in a credit line to 
the data. 
 
  
Copyright © and Moral Rights are retained by the author(s) and/ or other copyright 
owners. A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. This item cannot be reproduced or quoted extensively 
from without first obtaining permission in writing from the copyright holder(s). The 
content must not be changed in any way or sold commercially in any format or medium 
without the formal permission of the copyright holders. 
STUDY PROTOCOL Open Access
Protocol for a randomised controlled
feasibility trial of exercise rehabilitation for
people with postural tachycardia syndrome:
the PULSE study
Gordon McGregor1,2,3* , Siew Wan Hee4, Helen Eftekhari5, Nikki Holliday2, Gemma Pearce2, Harbinder Sandhu3,
Jane Simmonds6, Shivam Joshi7, Lesley Kavi8, Julie Bruce3, Sandeep Panikker5, Boon Lim9 and Sajad Hayat10
Abstract
Background: Postural orthostatic tachycardia syndrome (POTS) is an autonomic nervous system disorder causing
an abnormal cardiovascular response to upright posture. It affects around 0.2% of the population, most commonly
women aged 13 to 50 years. POTS can be debilitating; prolonged episodes of pre-syncope and fatigue can severely
affect activities of daily living and health-related quality of life (HRQoL). Medical treatment is limited and not
supported by randomised controlled trial (RCT) evidence. Lifestyle interventions are first-line treatment, including
increased fluid and salt intake, compression tights and isometric counter-pressure manoeuvres to prevent fainting.
Observational studies and small RCTs suggest exercise training may improve symptoms and HRQoL in POTS, but
evidence quality is low.
Methods: Sixty-two people (aged 18–40 years) with a confirmed diagnosis of POTS will be invited to enrol on a
feasibility RCT with embedded qualitative study. The primary outcome will be feasibility; process-related measures
will include the number of people eligible, recruited, randomised and withdrawn, along with indicators of exercise
programme adherence and acceptability. Secondary physiological, clinical and health-related outcomes including
sub-maximal recumbent bike exercise test, active stand test and HRQoL will be measured at 4 and 7months post-
randomisation by researchers blinded to treatment allocation. The PostUraL tachycardia Syndrome Exercise (PULSE)
intervention consists of (1) individual assessment; (2) 12-week, once to twice-weekly, supervised out-patient exercise
training; (3) behavioural and motivational support; and (4) guided lifestyle physical activity. The control intervention
will be best-practice usual care with a single 30-min, one-to-one practitioner appointment, and general advice on
safe and effective physical activity. For the embedded qualitative study, participants (n = 10 intervention, n = 10
control) will be interviewed at baseline and 4months post-randomisation to assess acceptability and the feasibility
of progressing to a definitive trial.
(Continued on next page)
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Discussion: There is very little high-quality research investigating exercise rehabilitation for people with POTS. The
PULSE study will be the first randomised trial to assess the feasibility of conducting a definitive multicentre RCT
testing supervised exercise rehabilitation with behavioural and motivational support, compared to best-practice
usual care, for people with POTS.
Trial registration: ISRCTN45323485 registered on 7 April 2020.
Keywords: Postural orthostatic tachycardia syndrome, Exercise, Rehabilitation, Dysautonomia, Cardiac rehabilitation,
Randomised controlled trial, Complex intervention, Feasibility
Background
Postural orthostatic tachycardia syndrome (POTS) affects the
autonomic nervous system resulting in an abnormal cardio-
vascular response to upright posture. It is defined as a clinical
syndrome that is usually characterised by (1) frequent symp-
toms that occur with standing such as light-headedness, pal-
pitations, tremulousness, generalised weakness, blurred
vision, exercise intolerance and fatigue; (2) an increase in
heart rate of ≥ 30 beats per minute when moving from a re-
cumbent to a standing position held for more than 30 s; and
(3) the absence of orthostatic hypotension (> 20mmHg drop
in systolic blood pressure) [1]. The pathophysiology of POTS
is multi-factorial. Symptoms may result from a multitude of
mechanisms, including but not limited to volume depletion,
immune dysfunction or autoimmune disease, cardiac and
physical deconditioning and the inability of lower limb vaso-
constriction to compensate for postural blood volume shifts
[2]. A disproportionate autonomic response, aimed at rectify-
ing haemodynamic compromise, results in the hallmark fea-
tures of prolonged pre-syncope (feeling of being about to
faint) and fatigue [1, 3].
POTS can be debilitating; simple activities may result
in persistent orthostatic intolerance. This can lead to
poor concentration, palpitations, nausea, ‘brain fog’ and
exercise intolerance [3] affecting activities of daily living
and health-related quality of life (HRQoL) [4]. Hypermo-
bility spectrum disorders (HSD) are a common comor-
bidity [5]. The ability to attend education, undertake
gainful employment and care for dependants can be sub-
stantially compromised by POTS. A constellation of
symptoms can initiate a negative feedback loop by which
enforced inactivity further precipitates orthostatic in-
tolerance, immobility and deconditioning [6, 7].
Treatment for POTS is limited; medical therapies have not
been tested in randomised controlled trials (RCTs) [8]. Ac-
cording to expert consensus, non-pharmacological therapy is
first-line treatment [1]. Conservative measures include in-
creased fluid and salt intake, compression tights, isometric
counter-pressure manoeuvres (e.g. hand gripping and leg
crossing/tensing) to prevent fainting, and psychological inter-
ventions to help manage chronic illness [1]. Exercise training
is also advocated as an essential component of POTS treat-
ment [1]. However, this is based on only two small studies,
one of which excluded people with HSD [9] and one which
investigated orthostatic intolerance in military recruits [10].
These studies demonstrated some physiological improve-
ment (increased left ventricular mass/blood volume and
decreased standing heart rate), reduced symptoms and im-
proved HRQoL. More recently, a prospective observational
study (n = 251) enrolled people with POTS on 3months of
unsupervised community exercise [8]. A total of 103 people
completed the treatment, of which 73 no longer met the
diagnostic criteria for POTS, and HRQoL was improved.
However, the study was limited by the lack of a control
group, and poor individualisation and supervision of exercise,
leading to 60% attrition.
Rationale for a trial
Supervised exercise rehabilitation may be an effective therapy
for POTS, with resultant clinical and psychosocial benefit.
Observational studies, whilst not definitive, suggest that
symptoms and psychosocial morbidity may improve [8].
Based on this preliminary evidence, it is important to investi-
gate whether or not people with POTS can benefit from su-
pervised exercise rehabilitation. The broad spectrum of
physical ability, symptoms and comorbidities requires that
this be initially undertaken within well-designed clinical trials
that take account of previous research limitations. The first
step is to investigate the feasibility of conducting a multi-
centre RCT testing a comprehensive exercise rehabilitation
intervention, compared to best-practice usual care, for people
with POTS.
Methods/design
Aim
The aim of the PostUraL tachycardia Syndrome Exercise
(PULSE) study is to assess the feasibility of conducting a
multi-centre RCT testing a supervised exercise rehabili-
tation intervention with behavioural and motivational
support (PULSE intervention) compared to best-practice
usual care for people with POTS.
Objectives
Undertake a feasibility RCT: Sixty-two participants (n
= 31 intervention, n = 31 control) will be randomised to
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the PULSE intervention or control. Process-related mea-
sures will include eligibility, recruitment, uptake and
intervention adherence. Physiological, clinical and
health-related measures will include a sub-maximal
graded recumbent bike exercise test, active stand test
and HRQoL.
Conduct a qualitative analysis: To explore perceptions,
opinions, acceptability and experiences of trial proce-
dures, the PULSE intervention and outcome measures,
interviews will be conducted with a sample of partici-
pants, drop-outs, and those who declined participation.
Study design and setting
PULSE is a two-arm feasibility RCT with an embedded
qualitative study (Fig. 1). Recruiting simultaneously from
two NHS POTS clinics in England (University Hospitals
Coventry & Warwickshire (UHCW) NHS Trust and Im-
perial College Healthcare NHS Trust), participants will
be randomised to the intervention or control arms in a
ratio of 1:1, stratified by NHS Trust. Table 1 summarises
study methods and design in accordance with the World
Health Organization (WHO) Trial Registration Data Set.
Eligibility criteria
People with POTS meeting the study inclusion criteria
are eligible to participate (Table 2).
Participant identification, recruitment and informed
consent
Physicians, arrhythmia nurse specialists or other clinical
staff involved in the care of people with POTS will iden-
tify eligible participants from two sources: (1) specialist
nurse/medical POTS out-patient clinics, (2) local sec-
ondary care disease registers. Participant information
leaflets will be provided in person during an out-patient
clinic appointment or will be sent in the post with a re-
quest to return an expression of interest form. Once
interest and willingness to be contacted have been con-
firmed, participants will be contacted by a member of
their clinical team and invited to attend a baseline as-
sessment appointment, at which eligibility will be reas-
sessed and informed consent taken. The PULSE study
requires different levels of consent: (1) to take part in
the trial; (2) for medical notes to be reviewed by desig-
nated individuals and personal identifiable information
to be securely stored; and (3) to allow telephone contact
between the trial team and the participant or designated
next of kin.
Randomisation, allocation concealment and blinding
After all baseline assessments have been completed, partici-
pants will be randomised on a 1:1 basis to intervention or
control, stratified by centre (UHCW NHS Trust or Imperial
College Healthcare NHS Trust) (Fig. 2). Randomisation will
be performed, and allocation concealment maintained, using
an online validated randomisation sequence generator, as
part of an electronic data capture system (Castor). Only
PULSE practitioners, who will be delivering either the control
or active interventions, will be informed of group allocation,
and only after all baseline measures are complete. Partici-
pants and practitioners cannot be blinded to group alloca-
tion. PULSE practitioners will deliver both the active and
control interventions, so will be aware of treatment allocation
after randomisation. Outcome assessment staff, the chief in-
vestigator (CI) and the trial statistician will be blinded to
group allocation, until statistical analysis is complete.
Interventions
The PULSE intervention
To ensure applicability and acceptability further to re-
ceipt of study grant funding, the intervention was refined
and finalised using co-production methods, in accord-
ance with INVOLVE [13]. A detailed account of this
process will be available in an intervention development
publication. Briefly, two workshops with patients, public
and stakeholders were led by experienced facilitators.
During the first workshop, proposed outcome measures
and the PULSE intervention were presented to the group
and discussed from all stakeholders’ perspectives. In-
terim work was then undertaken by the research team to
refine the intervention components and outcome mea-
sures prior to workshop two during which the protocol
was finalised and implementation and delivery were
discussed.
POTS patients and stakeholders (family, nursing,
psychology, exercise physiology, physiotherapy, general
practice, POTS UK) attended the meetings to ensure
that contributions were correctly interpreted [14]. Co-
production techniques allowed these multiple stake-
holders to work towards a common goal [13]. It was
a flexible and adaptable process, using multiple com-
munication strategies, to ensure inclusion of people
who were affected differently by POTS. The process
was iterative, with each session informing the next,
until a solution was achieved. Researcher notes were
analysed thematically, thus informing the refinement
and implementation of the PULSE intervention and
study [15].
Format: To ensure external validity to the NHS out-
patient/community outreach setting, the PULSE inter-
vention is based on existing UK cardio-pulmonary re-
habilitation guidelines and service design [16–18].
Programme design: Participants randomised to the
PULSE intervention will either (1) access existing cardio-
pulmonary rehabilitation programmes, i.e. they will
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exercise with people with a range of cardiopulmonary
conditions, as well as other trial participants randomised
to the PULSE intervention, or (2) they will attend dedi-
cated sessions for people with POTS. To encourage peer
support, every effort will be made to ensure there are at
least two to three PULSE participants exercising at the
same centre at the same time. The PULSE intervention
has four components:
Component 1: individual assessment and exercise
familiarisation
Individual assessment: Participants will undergo a 1-h,
one-to-one appointment with a PULSE ‘practitioner’
(clinical exercise physiologist), to assess and record med-
ical and physical activity history and medication and to
discuss goals, expectations and any concerns.
Fig. 1 Study flow chart
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Table 1 World Health Organization trial registration data set
Data category Information
Primary registry and trial
identifying number
ISRCTN45323485
Date of registration in primary
registry
7 April 2020
Secondary identifying numbers REC reference: 20/EM/0077
BHF reference: PG/19/22/34203
Source(s) of monetary or material
support
British Heart Foundation Project Grant
Primary sponsor UHCW NHS Trust
University Hospital
Clifford Bridge Rd., Coventry CV2 2DX
Tel: 02476 966195
Email: R&DSponsorship@uhcw.nhs.uk
Secondary sponsor(s) Coventry University
Richard Crossman Building
Jordon Well
Coventry University
CV1 5RW
Email: cdu141@coventry.ac.uk
Contact for public queries Coventry University
Richard Crossman Building
Jordon Well
Coventry University
CV1 5RW
Email: cdu141@coventry.ac.uk
Contact for scientific queries Dr Gordon McGregor
Coventry University/UHCW NHS Trust
Tel: 024 76150285
Email: gordon.mcgregor@coventry.ac.uk
Public title Supervised exercise rehabilitation for people with postural tachycardia syndrome
Scientific title PostUraL tachycardia Syndrome Exercise (PULSE): a randomised controlled feasibility study
Countries of recruitment England
Health condition(s) or problem(s)
studied
Postural orthostatic tachycardia syndrome
Intervention(s) Intervention group: (1) individual assessment, (2) supervised out-patient exercise programme, (3) behavioural and motiv-
ational support, (4) guided lifestyle physical activity.
Control intervention: best-practice usual care
Key inclusion and exclusion
criteria
Inclusion: adults (18–40 years) with confirmed diagnosis of POTS and attending syncope out-patient clinics; able to attend
a PULSE centre; able to provide informed consent.
Exclusion: absolute contraindications to exercise; currently achieving CMO physical activity guidelines; mental health issue
preventing engagement with trial procedures; pregnant at time of recruitment; previous randomisation in PULSE; unable
to attend a PULSE centre; took part in PULSE intervention co-creation.
Study type Type: feasibility, interventional, two-centre
Allocation: randomised
Assignment: parallel
Masking: outcomes assessors, chief investigator, statistician
Date of first enrolment TBC
Target sample size 62
Recruitment status Ready to start recruitment (on hold due to Covid-19)
Primary outcome(s) Feasibility and process indicators: number of patients screened, eligible, recruited, randomised, withdrawn and retained;
adherence to exercise rehabilitation programme; length of time to complete each outcome assessment and the whole
outcome assessment appointment; willingness of participants to join non-POTS specific exercise rehabilitation pro-
grammes; physiological, clinical, patient-reported outcomes to identify a primary outcome for a definitive trial; acceptability
of the interventions and the trial (qualitative interviews)
Key secondary outcomes At 4 and 7months: exercise capacity—graded recumbent cycle ergometer test; autonomic function—increase in heart
rate from supine to 10-min stand; symptom burden—COMPASS 31 dysautonomia scale and fatigue severity scale;
HRQoL—EQ-5D-5L; self-efficacy—general self-efficacy scale; exercise tolerability—continuous heart rate monitoring and
symptoms during exercise; adverse events.
At baseline and 7 months: semi-structured interviews with participants
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Exercise prescription: There are no accepted guidelines
for exercise training in POTS. The intervention will be
individualised and is based on existing evidence, patient
and public involvement (PPI) and co-production ses-
sions and the centres’ expertise in the provision of exer-
cise for clinical populations. As such, the PULSE
practitioner will prescribe a safe and effective individua-
lised exercise programme [11, 17] based on clinical in-
formation, data from graded, sub-maximal cycle
ergometry and active stand tests and patient-centred
goal setting.
Familiarisation sessions: Exercise instruction will be
provided on an individual basis during two one-on-one
familiarisation sessions in the first week of the
programme, and reinforced throughout, by PULSE prac-
titioners and clinical staff. Familiarisation sessions, con-
ducted within the cardiopulmonary rehabilitation
programmes, will enable participants to build confi-
dence, whilst PULSE practitioners refine and optimise
the exercise prescription. Behavioural and motivational
support will also be introduced during these sessions.
Component 2: supervised out-patient exercise programmes
For the first 6 (of 12) weeks, exercise will be undertaken
during one to two sessions per week solely in a con-
trolled gym environment with carefully staged progres-
sion in response to participant tolerance and symptoms.
For those that are able, moderate intensity dynamic car-
diovascular exercise will be prescribed. In addition,
‘functional fitness training’ will aim to improve ortho-
static tolerance and general musculoskeletal decondi-
tioning. This type of training is targeted specifically at
the components of physical fitness required for activities
of daily living, making use of multi-plane motion, to im-
prove agility, coordination, proprioception, balance and
functional strength.
Prescribed exercise: Exercise will be versatile and indi-
vidualised, incorporating cardiovascular and functional
resistance training components. Interval or continuous
cardiovascular exercise will be performed at a tolerable
intensity (regulated with rating of perceived exertion
[RPE] and symptoms) for a manageable time, focusing
initially on exercises in the recumbent or semi-
recumbent position (e.g. rowing machine, recumbent
cycle ergometer) to minimise orthostatic tachycardia.
Gentle warm-up and cool down will be performed in the
manner best suited to individual symptoms. Exercise in-
tensity and time will be gradually increased, and upright
exercise introduced as tolerated.
Component 3: behavioural and motivational support
Comprehensive behavioural change and motivational
strategies to improve adherence and compliance to exer-
cise will be incorporated into the PULSE intervention.
Every second week, before or after their supervised exer-
cise session, participants will receive a one-to-one, 30-
min behavioural and motivational session delivered by a
trained PULSE practitioner, with the aim of improving
short- and long-term adherence to exercise.
The PULSE intervention will be based on a cognitive
behavioural framework including self-efficacy and self-
management principles with behaviour change theory
[19]. In particular, the COM-B model of behaviour
change (‘capability’, ‘opportunity’, ‘motivation’ and ‘be-
haviour’) will be applied to the content and delivery of
the behavioural sessions. Capability relates to increasing
confidence through supervised exercise practice and ex-
ploring participants’ own health beliefs and perceived
barriers which may prevent them from progressing with
the intervention. For example, quite often people with
POTS may avoid certain activities and movement due
to a fear of aggravating symptoms [20]. Opportunity,
both internal and external to the individual, will be ex-
plored through beliefs and thoughts in relation to
knowledge and acceptance of POTS, including princi-
ples of self-management and skills of living with what
is sometimes termed ‘the invisible condition’. Access to
material and information covered in the sessions will be
ensured by producing a participant handbook to allow
consolidation of learning and reflection in between ses-
sions. Motivation will also be key to sustained behav-
iour change for people with POTS. This will be
addressed with planning, goal setting and exploration
of expectations, with opportunity for self-reflection and
discussion of progress, setbacks and overcoming
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
▪ Adults 18 to 40 years of age
▪ Confirmed diagnosis of POTS [1]
and currently attending specialist
out-patient clinics
▪ Able to attend a PULSE centre 1–
2 times/week for 8–12 weeks for
exercise training
▪ Able to provide informed
consent
▪ Absolute contraindications to
exercise as per international clinical
guidelines [11, 12]
▪ Any serious mental health/
cognitive issue that will prevent
engagement with study
procedures or increase the risk of
exercise complications
▪ Unable to make suitable travel
arrangements
▪ Currently undertaking structured
exercise/physical activity equivalent
to the Chief Medical Officer (CMO)
guidelines (150 min moderate
exercise per week or 60min
vigorous per week)
▪ Previous randomisation in the
present trial
▪ Pregnancy
▪ Taken part in co-creation work-
shops to design the PULSE inter-
vention/study
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obstacles [21]. This will be combined with the theory of
planned behaviour [22, 23] to explore participant’s per-
ceived control, intention and motivation to adhere to
the PULSE intervention.
The PULSE practitioners will be trained to use open
questions and motivational interviewing to assess partic-
ipants’ current beliefs and encourage behaviour change.
In accordance with existing literature, it will be import-
ant to manage expectations. Previous work in POTS has
indicated that symptoms may worsen for 4–6 weeks be-
fore a lasting benefit is gained [21].
Component 4: lifestyle physical activity
Half-way through the supervised exercise intervention,
thus after 6 weeks of centre-based exercise has been
safely completed, and/or individual exercise tolerance
has been evaluated, participants will be encouraged to
undertake self-directed, lifestyle physical activity at
home in addition to the supervised sessions. This will
help ensure that exercise is performed every other
day. Activities such as swimming, walking and cycling
will be encouraged for those in whom it is
appropriate.
Fig. 2 Schedule of enrolment, interventions and assessments
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Control intervention: best practice usual care
Participants in the control arm will be provided with
freely available advice on lifestyle physical activity (POTS
UK website) [24] during a one-to-one session, lasting ap-
proximately 30 min, with a PULSE practitioner. They
will not receive any further input during the control
intervention period. Participants will be permitted to
continue with any current physical activity but will not
receive supervised exercise training or behavioural and
motivational sessions from PULSE practitioners.
Safety
The PULSE intervention will be delivered in cardiopulmo-
nary rehabilitation units with qualified staff and appropri-
ate emergency equipment. Lifestyle physical activity will
be lower intensity and replicate exercises performed in the
gym under supervision. Intervention practitioners will be
clinical exercise physiologists, experienced in assessment,
prescription and delivery of exercise in clinical popula-
tions and trained in the standardised delivery of the
PULSE intervention. Additional training in exercise modi-
fication to avoid joint subluxation and dislocation in
hypermobile participants will be provided by a specialist
physiotherapist.
Primary outcome
The primary outcome will be overall feasibility and
process-related measures:
 Number of patients screened, eligible, recruited,
randomised, withdrawn and retained.
 Adherence to exercise rehabilitation
programme—number of supervised exercise and
lifestyle physical activity sessions completed over 12
weeks.
 Length of time to complete each outcome measure
and the whole outcome assessment appointment.
 Willingness of participants to join non-POTS spe-
cific exercise rehabilitation programmes (i.e. stand-
ard cardiopulmonary rehabilitation programmes).
Participant preference will be recorded, and uptake
to each programme model monitored.
 Physiological, clinical, patient-reported outcomes to
confirm/identify a primary outcome for a definitive
trial.
 Acceptability of the interventions and the trial
(embedded qualitative study).
Secondary outcomes
Physiological, clinical and patient-reported outcomes
will be assessed during study visits at baseline, and post-
intervention at 4 and 7months post-randomisation
(Table 2).
Exercise capacity will be measured with a graded sub-
maximal recumbent cycle ergometer assessment [11].
This will be a simple test (maximum 10min) involving
gradual increments in workload every minute. Workload
increments and test termination will be determined by
symptoms, heart rate, blood pressure and RPE responses
which will be recorded throughout. The increase in
heart rate from supine to 10-min stand test (active stand
test) will be conducted as per clinical practice [25]. This
is a commonly used diagnostic test for POTS, measuring
the heart rate response to 10 min (or however long is
manageable dependant on symptoms) of standing. It will
be performed only as an outcome measure in this trial,
not for diagnostic purposes.
The symptom burden of POTS will be measured with
the Composite Autonomic Symptom Score (COMPASS
31) dysautonomia scale [26]. This is a self-rating ques-
tionnaire evaluating six domains of autonomic function:
orthostatic intolerance, vasomotor, secretomotor, gastro-
intestinal, bladder and pupillomotor domains. In
addition to domain scores, an overall total score from 0
to 100 can be computed, with a higher score indicating a
greater disease burden. Health-related quality of life will
be evaluated with the EQ-5D-5L [27], a validated, gen-
eric HRQoL measure consisting of five dimensions, each
with five levels of response. It has good test-retest reli-
ability, is simple to use and gives a single preference-
based index value for health status. The Fatigue Severity
Scale [28], a validated nine-item questionnaire, will be
used to assess disabling fatigue. Each item is rated on a
seven-point scale, from strongly disagree to strongly
agree. A total score is derived from all nine questions; a
higher score indicates a greater impact of fatigue on
everyday activities. Self-efficacy will be measured with
the generalised self-efficacy scale [29] which is a 10-item
psychometric scale designed to assess optimistic self-
beliefs to cope with a variety of difficult demands in life.
A single score between 10 and 40 is generated; greater
self-efficacy is represented by a higher score.
To evaluate the participants’ response to exercise ses-
sions and assessments, any POTS-related or associated
symptoms will be recorded. Adverse and serious adverse
events will be documented and reported to the trial
management group (TMG) in accordance with the prin-
ciples of good clinical practice (GCP).
Sample size
This is a feasibility RCT to assess recruitment, uptake,
adherence, acceptability and clinical, physiological and
health-related outcomes. Thus, the sample size is not
based on a power calculation. Nevertheless, the aim is to
estimate any possible effect of the change of heart rate
from supine to 10-min stand between the two treatment
arms to inform a future definitive RCT. The sample size
McGregor et al. Pilot and Feasibility Studies           (2020) 6:157 Page 8 of 11
is determined using the confidence interval approach to
provide a given level of precision. From a single-arm
study investigating a 3-month community exercise
programme in a similar population [8], the mean in-
crease in heart rate from supine to 10-min stand at base-
line was 46 ± 17 bpm and post-intervention was 23 ± 14
bpm. For the purpose of this trial, the standard deviation
(SD) is assumed to be the same for both treatment arms,
and the SD of the difference of the change is 17 bpm.
Therefore, the total sample size required to obtain a 95%
confidence interval width of 20 bpm is 46 participants
[30]. Assuming a drop-out rate of 25%, the total sample
size required is 62 participants (31 per treatment arm).
Participants will be randomised equally to the interven-
tion or usual care arms (i.e. 1:1 ratio).
Data analysis
Participant demographics and physiological, clinical and
patient-reported outcomes will be summarised by treat-
ment arms as mean and SD, median and interquartile
range (for continuous data) or frequency and percentage
(for categorical data) at baseline, and 4 and 7months
post-randomisation. The primary outcome is feasibility;
therefore, process indicators relating to recruitment and
intervention delivery will be assessed. Descriptive statis-
tics will be presented by recruitment centre and treat-
ment arm. The difference in outcomes between
treatment arms at 4 and 7months post-randomisation
and the difference of the change from baseline to 4
months post-randomisation between arms will be com-
puted. All estimates will be reported with a 95% confi-
dence interval. No formal hypothesis testing will be
performed.
All data will be analysed and reported in accordance
with the CONSORT statement. All primary analyses are
planned on an intention-to-treat basis (i.e. data will be
analysed according to the treatment arm the participant
was originally allocated to, irrespective of what treat-
ment they actually received) with a secondary per proto-
col analysis.
Embedded qualitative study
Semi-structured interviews, conducted by an experi-
enced qualitative researcher, with approximately n = 10
intervention group and n = 10 usual care, at baseline
and 4months post-randomisation (same participants at
both time-points), will be digitally recorded, pseudony-
mised and transcribed verbatim. Data will be analysed
using the framework method [31], broadly as follows:
 Data familiarisation: reading of complete interview
transcripts, listening to original audio recordings and
use of field notes;
 Identifying a thematic framework: key issues,
concepts and themes will be identified, and an index
of codes developed;
 Indexing: the index generated through identification
of the thematic framework will be applied to all
data;
 Charting: a summary of each passage of text will be
transferred into a chart to allow more overall and
abstract consideration of index codes across the data
set and by each individual;
 Mapping and interpretation: understanding the
meaning of key themes, dimensions and the broad
overall picture of the data and identifying and
understanding the typical associations between
themes and dimensions.
The charting process will provide an opportunity to
code data from numerous perspectives. The computer
package NVivo will be used to organise the analysis. The
findings of the qualitative analyses will be reported as a
separate chapter in the final report but will also be in-
corporated in the discussion to bring together a synthe-
sis of all the results, thus helping to explore and explain
the overall ‘value’ of the interventions. Quantitative and
qualitative data will be integrated using a mixed methods
matrix where quantitative responses can be compared to
interview data and recorded on a matrix [32].
Transition to a definitive trial
The ADePT (A Process for Decision-making after Pilot
and Feasibility Trials) framework [33] will be used to
identify and examine issues and problems methodically,
and to appraise and find appropriate solutions to inform
the decision-making process to transition from this two-
centre feasibility trial to a definitive multi-centre RCT.
Data collection and management
Personal data collected during the study will be handled
and stored in accordance with General Data Protection
Regulation (GDPR). Personal identifying information will
be stored at each site for follow-up purposes. Disclosure
of confidential information will only be considered if
there is an issue which may jeopardise the safety of the
participant or another person, in accordance with local
standard operating procedures (SOPs) and the UK regu-
latory framework. An online validated, GCP compliant,
electronic data capture system (Castor) will be used by
researchers at each site to record and store study data.
All data will be pseudonymised after the collection of
baseline demographics for each participant. Participants
will be assigned a unique study ID, which will be used to
identify all documents associated with that participant
for the duration of the study. In line with participant
consent, direct access to source data/documents will be
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granted to authorised representatives from the sponsor,
host institution and the regulatory authorities, to permit
study-related monitoring, audits and inspections.
Trial monitoring
The trial management group (TMG), chaired by the CI,
and consisting of project management staff, lay repre-
sentatives, co-investigators, the trial statistician and
sponsor representatives, will meet monthly for the dur-
ation of the project. For this small feasibility RCT, there
will be no independent data monitoring committee or
trial steering committee; these functions will be com-
pleted by the TMG.
Adverse event management
An adverse event (AE) will be defined as any untoward
medical occurrence involving a participant, which does
not necessarily have a causal relationship with the inter-
vention or trial. Expected AEs for the PULSE study that
will be recorded but not reported include pre-syncope,
muscle and joint stiffness, soreness and dislocation and
tiredness and fatigue. Any unexpected AEs related to
PULSE will be recorded and reported to the TMG. Ser-
ious adverse events (SAEs) that have no causal relation-
ship with PULSE will not be reported to oversight
committees. Causality and expectedness will be con-
firmed by the CI with clinician support. SAEs deemed to
be unexpected and possibly, probably or definitely re-
lated to PULSE will be notified to the Research Ethics
Committee (REC) within 15 days. All AEs and SAEs will
be recorded within 24 h of the investigator being made
aware.
Patient and public involvement
The PULSE intervention components were initially de-
veloped based on existing evidence, previous clinical
work at our centres and extensive patient and public in-
volvement (PPI). Eighteen people with POTS partici-
pated in teleconference consultation prior to the grant
funding application. The intervention was further devel-
oped and refined during two co-creation workshops with
multiple stakeholders (as outlined in more detail above).
Lay representatives will sit on the TMG and will be in-
vited to contribute to dissemination and reporting on
completion of the study.
Discussion
Postural orthostatic tachycardia syndrome can be a de-
bilitating condition, with pre-syncope and fatigue,
amongst other symptoms, significantly impacting on ac-
tivities of daily living and HRQoL. Whilst prevalence is
estimated to be between 0.2 and 1%, it is increasingly
recognised that POTS is commonly misdiagnosed, thus
prevalence is likely to be much higher. In the absence of
effective and appropriately tested medical and pharma-
cological therapies, lifestyle interventions have the po-
tential to improve symptoms and help manage this long-
term condition.
Exercise rehabilitation is not routinely offered to people
with POTS as it has not been evaluated in well-designed
clinical trials. Preliminary reports from non-randomised
controlled studies indicate that exercise rehabilitation pro-
grammes, as provided almost universally for people with
long-term cardiac and pulmonary conditions, may be
beneficial for people with POTS. The PULSE study will be
the first to assess the feasibility of an exercise intervention
with behavioural and motivational support for people with
POTS, to inform whether or not a future multi-centre
RCT investigating clinical and cost-effectiveness can be
delivered in the NHS. The feasibility of a supervised exer-
cise programme, a behavioural and motivational support
intervention, and a number of important clinical, physio-
logical and patient-reported outcome measures, will be
evaluated within the framework of a feasibility RCT. If
feasibility is proven, a definitive multi-centre RCT should
be conducted in the future.
Trial status
All approvals are in place, and the trial is ready to begin
recruitment. Currently, all trial activities have been tem-
porarily suspended due to the COVID-19 pandemic.
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